Goldman Sachs Group Inc Sarepta Therapeutics, Inc. Transaction History

Goldman Sachs Group Inc

  • $605 Billion
  • Q3 2024

A detailed history of Goldman Sachs Group Inc transactions in Sarepta Therapeutics, Inc. stock. As of the latest transaction made, Goldman Sachs Group Inc holds 301,021 shares of SRPT stock, worth $36.5 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares
301,021
Previous 439,577 31.52%
Holding current value
$36.5 Million
Previous $69.5 Million 45.87%
% of portfolio
0.01%
Previous 0.01%

Shares

19 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024
SELL
$124.33 - $156.75 $17.2 Million - $21.7 Million
-138,556 Reduced 31.52%
301,021 $37.6 Million
Q2 2024

Aug 13, 2024
BUY
$113.33 - $163.85 $21.5 Million - $31.1 Million
189,530 Added 75.8%
439,577 $69.5 Million
Q1 2024

May 15, 2024
BUY
$93.7 - $141.53 $6.11 Million - $9.22 Million
65,177 Added 35.26%
250,047 $32.4 Million
Q4 2023

Feb 13, 2024
SELL
$67.31 - $124.76 $37.6 Million - $69.6 Million
-558,022 Reduced 75.11%
184,870 $17.8 Million
Q3 2023

May 14, 2024
BUY
$102.5 - $123.59 $57.2 Million - $69 Million
558,022 Added 301.85%
742,892 $90.1 Million
Q3 2023

Nov 14, 2023
SELL
$102.5 - $123.59 $23.2 Million - $28 Million
-226,396 Reduced 23.36%
742,892 $90.1 Million
Q2 2023

May 14, 2024
BUY
$106.4 - $157.19 $22.5 Million - $33.2 Million
211,216 Added 27.86%
969,288 $111 Million
Q2 2023

Aug 14, 2023
BUY
$106.4 - $157.19 $22.5 Million - $33.2 Million
211,216 Added 27.86%
969,288 $111 Million
Q1 2023

May 14, 2024
SELL
$117.53 - $155.99 $56.5 Million - $75 Million
-480,755 Reduced 38.81%
758,072 $104 Million
Q1 2023

May 11, 2023
SELL
$117.53 - $155.99 $56.5 Million - $75 Million
-480,755 Reduced 38.81%
758,072 $104 Million
Q4 2022

May 14, 2024
BUY
$100.86 - $132.13 $10.3 Million - $13.5 Million
102,134 Added 8.99%
1,238,827 $161 Million
Q4 2022

Feb 13, 2023
BUY
$100.86 - $132.13 $10.3 Million - $13.5 Million
102,134 Added 8.99%
1,238,827 $161 Million
Q3 2022

May 14, 2024
SELL
$75.71 - $119.24 $20.8 Million - $32.7 Million
-274,230 Reduced 19.44%
1,136,693 $126 Million
Q3 2022

Nov 10, 2022
SELL
$75.71 - $119.24 $20.8 Million - $32.7 Million
-274,230 Reduced 19.44%
1,136,693 $126 Million
Q2 2022

May 14, 2024
BUY
$62.69 - $88.44 $76.9 Million - $108 Million
1,226,053 Added 663.2%
1,410,923 $106 Million
Q2 2022

Aug 15, 2022
BUY
$62.69 - $88.44 $30.5 Million - $43.1 Million
486,867 Added 52.69%
1,410,923 $106 Million
Q1 2022

May 16, 2022
SELL
$63.15 - $90.42 $5.19 Million - $7.43 Million
-82,149 Reduced 8.16%
924,056 $72.2 Million
Q4 2021

Feb 14, 2022
BUY
$77.28 - $99.42 $10.3 Million - $13.2 Million
133,210 Added 15.26%
1,006,205 $90.6 Million
Q3 2021

Nov 10, 2021
BUY
$65.97 - $92.48 $57.6 Million - $80.7 Million
872,995 New
872,995 $80.7 Million

Others Institutions Holding SRPT

# of Institutions
529
Shares Held
84.2M
Call Options Held
2.06M
Put Options Held
1.52M
View Full List

About Sarepta Therapeutics, Inc.

SRPT Quotes by TradingView
  • Ticker SRPT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 87,567,904
  • Market Cap $10.6B
  • Description
  • Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mut...
More about SRPT
Track This Portfolio

Track Goldman Sachs Group Inc Portfolio

Follow Goldman Sachs Group Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Goldman Sachs Group Inc, based on Form 13F filings with the SEC.

News

Stay updated on Goldman Sachs Group Inc with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email